Home › Funds › Eversept Partners, LP › CLDX

Eversept Partners, LP position in CLDX

CELLDEX THERAPEUTICS INC NEW · Health Care

Eversept Partners, LP reported holding 1,174,771 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q3 2026 13F filing — a position valued at US$38.1M, representing 2.05% of its reported portfolio and ranking #13 among its reported holdings. Eversept Partners, LP has disclosed CLDX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.17M sh
Reported value held$38.07M
Portfolio Weight2.05%
First reportedQ3 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Eversept Partners, LP's CLDX position evolved

Eversept Partners, LP first disclosed a stake in CLDX in Q3 2023 at 588,143 shares (US$16.2M). The position peaked in Q2 2026 at 1,785,941 shares, worth US$66.5M. Across 13 filings, Eversept Partners, LP increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,174,771 shares valued at US$38.1M — a reduction of -611,170 shares quarter over quarter.. Notable position changes include a 28% increase in Q4 2023 (shares rose 6% over the following quarter), a 38% increase in Q3 2025 (shares rose 5% over the following quarter), a 34% trim in Q3 2026 (shares fell 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 588.14K $16.19M New
Q4 2023 754.11K $29.91M Add
Q1 2024 711.12K $29.85M Reduce
Q2 2024 633.01K $23.43M Reduce
Q3 2024 564.90K $19.20M Reduce
Q4 2024 719.84K $18.19M Add
Q1 2025 696.50K $12.64M Reduce
Q2 2025 838.74K $17.07M Add
Q3 2025 1.15M $29.85M Add
Q4 2025 1.43M $38.97M Add
Q1 2026 1.79M $56.72M Add
Q2 2026 1.79M $66.45M Hold
Q3 2026 1.17M $38.07M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CLDX and 13F data

CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 39 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$164.2M), Deep Track Capital, LP (US$68.9M), EVENTIDE ASSET MANAGEMENT, LLC (US$61.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CLDX

All CLDX fund holders →

FAQ

How long has Eversept Partners, LP held CLDX?

Eversept Partners, LP has disclosed CLDX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Eversept Partners, LP's current position in CLDX?

As of Q3 2026, Eversept Partners, LP holds 1.17M shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $38.07M, representing 2.05% of its reported portfolio and ranking #13.

Has Eversept Partners, LP been buying or selling CLDX?

In the latest 13F filing (Q3 2026), Eversept Partners, LP reduced its position in CLDX. The position peaked in Q2 2026 at 1.79M shares.

Which other funds hold CLDX?

Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, EVENTIDE ASSET MANAGEMENT, LLC, among 39 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.